glp-1 alcohol use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance disorders: An emerging pharmacotherapeutic target GLP-1 receptor agonists for the

These are complementary rather than conflicting effects

a non-GLP-1 agonist show that overall, thyroid cancer is increased in people who take GLP-1s

However, two out of the four found a trend toward reduced glutathione in schizophrenia [24, 25] and in one, lowered levels of glutathione were associated with negative symptoms [24]

Sources New England Journal of Medicine: Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics: Semaglutide for the treatment of overweight and obesity: A review JAMA Network: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity American Diabetes Association: Standards of Medical Care in Diabetes, 2025 Harvard Health Publishing: GLP-1 diabetes and weight-loss drug side effects: Ozempic face and more University of Illinois Chicago: What efficacy data are available on the use of tirzepatide for obesity

And users who can't get insurance coverage, may be able to get the drug for as low as $550 a month

By understanding the process, they felt more in control of their progress